{"transactions":[{"id":741689,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:52:24.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":20215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":20215,"derivative":{"exercise_price":20,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":20215},"source":{"system":"sec-edgar","filing":"0001193125-26-267797","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526267797/ownership.xml","form_type":"4"}},{"id":1080708,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T17:15:32.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":5.73,"underlying":"Common Stock","underlying_shares":42200},"source":{"system":"sec-edgar","filing":"0000950170-25-099263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025099263/ownership.xml","form_type":"4"}},{"id":1080707,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T17:15:32.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":136139,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":5.02,"underlying":"Common Stock","underlying_shares":136139},"source":{"system":"sec-edgar","filing":"0000950170-25-099263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025099263/ownership.xml","form_type":"4"}},{"id":1080706,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-28T17:15:32.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":1800000,"ownership":{"direct":false,"nature":"By GV 2023, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities reported in this row are directly beneficially owned by GV 2023, L.P. (the \"2023 Partnership\"). GV 2023 GP, L.P. (the \"2023 GP\") is the general partner of the 2023 Partnership. GV 2023 GP, L.L.C. (\"GV 2023 LLC\") is the general partner of the 2023 GP. Alphabet Holdings is the sole member of GV 2023 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2023 Partnership. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(continued from footnote 7) Dr. Yeshwant is an affiliate of the 2023 Partnership but does not have voting or dispositive power over the shares held by the 2023 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2023 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-099263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025099263/ownership.xml","form_type":"4"}},{"id":1080705,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-28T17:15:32.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":4260047,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole member of GV 2019 LLC is Alphabet Holdings. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"(continued from Footnote 5) Dr. Yeshwant is an affiliate of the 2019 Partnership but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-099263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025099263/ownership.xml","form_type":"4"}},{"id":1080704,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-28T17:15:32.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":6108442,"ownership":{"direct":false,"nature":"By GV 2017 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported in this row are directly held by GV 2017, L.P. (the \"2017 Partnership\"). The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the \"2017 GP\"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. (\"GV 2017 LLC\"). The sole member of GV 2017 LLC is Alphabet Holdings LLC (\"Alphabet Holdings\"). The sole member of Alphabet Holdings is XXVI Holdings Inc. (\"XXVI\"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(continued from footnote 3) Dr. Yeshwant is an affiliate of the 2017 Partnership but does not have voting or dispositive power over the shares held by the 2017 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2017 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-099263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025099263/ownership.xml","form_type":"4"}},{"id":1119860,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T17:00:18.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":42200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":42200,"derivative":{"exercise_price":5.73,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":42200},"source":{"system":"sec-edgar","filing":"0000950170-25-083226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025083226/ownership.xml","form_type":"4"}},{"id":1467322,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-28T07:45:13.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":136139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":136139,"derivative":{"exercise_price":5.02,"expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":136139},"source":{"system":"sec-edgar","filing":"0000950170-24-078786","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017024078786/ownership.xml","form_type":"4"}},{"id":1721983,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T16:30:09.000Z","date":"2023-12-01","kind":"purchase","planned":false,"acquired":true,"shares":1800000,"price":10,"value":18000000.0,"ownership":{"direct":false,"nature":"By GV 2023, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported in this row are directly beneficially owned by GV 2023, L.P. (the \"2023 Partnership\"). GV 2023 GP, L.P. (the \"2023 GP\") is the general partner of the 2023 Partnership. GV 2023 GP, L.L.C. (\"GV 2023 LLC\") is the general partner of the 2023 GP. Alphabet Holdings LLC (\"Alphabet Holdings\") is the sole member of GV 2023 LLC. XXVI Holdings Inc. (\"XXVI\") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")) the securities directly beneficially owned by the 2023 Partnership. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from footnote 1) Dr. Yeshwant is an affiliate of the 2023 Partnership but does not have voting or dispositive power over the shares held by the 2023 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2023 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":1800000,"source":{"system":"sec-edgar","filing":"0000950170-23-068199","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017023068199/ownership.xml","form_type":"4"}},{"id":1745830,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-09T16:12:09.000Z","date":"2023-11-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":101010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the \"Merger Agreement\"), by and among the Issuer, Revolution Medicines, Inc. (\"Revolution Medicines\"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub I\"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines (\"Merger Sub II\"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the \"Effective Time\"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the \"First Merger\"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an \"In-the-Money Option\") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration)."}],"balance_after":0,"derivative":{"exercise_price":4.95,"expiration_date":"2032-09-30","underlying":"Common Stock","underlying_shares":101010},"source":{"system":"sec-edgar","filing":"0000899243-23-020300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924323020300/doc4.xml","form_type":"4"}},{"id":1849764,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T17:00:16.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":26642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":26642,"derivative":{"exercise_price":19.84,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":26642},"source":{"system":"sec-edgar","filing":"0001209191-23-038470","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000120919123038470/doc4.xml","form_type":"4"}},{"id":2122378,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-08T17:51:29.000Z","date":"2022-11-04","kind":"sale","acquired":false,"shares":243,"price":32.9,"value":7994.7,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from Footnote 7) Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4260047,"source":{"system":"sec-edgar","filing":"0000899243-22-035380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035380/doc4.xml","form_type":"4"}},{"id":2122377,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-08T17:51:29.000Z","date":"2022-11-04","kind":"sale","acquired":false,"shares":650,"price":31.9905,"value":20793.825,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 to $32.20, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from Footnote 7) Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4260290,"source":{"system":"sec-edgar","filing":"0000899243-22-035380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035380/doc4.xml","form_type":"4"}},{"id":2122376,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-08T17:51:29.000Z","date":"2022-11-04","kind":"sale","acquired":false,"shares":47690,"price":31.118,"value":1484017.42,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.51 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 5 and footnote 6 of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from Footnote 7) Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4260940,"source":{"system":"sec-edgar","filing":"0000899243-22-035380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035380/doc4.xml","form_type":"4"}},{"id":2122375,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-08T17:51:29.000Z","date":"2022-11-04","kind":"other","acquired":false,"shares":48583,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By GV 2017 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a pro rata in-kind distribution, for no consideration, by GV 2017, L.P. (the \"2017 Partnership\") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2017 Partnership's affiliate, Alphabet Holdings LLC (\"Alphabet Holdings\"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are directly held by the 2017 Partnership. The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the \"2017 GP\"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. (\"GV 2017 LLC\"). The sole managing member of GV 2017 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI Holdings Inc. (\"XXVI\"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of the 2017 GP but does not have voting or dispositive power over the shares held by the 2017 Partnership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from footnote 2) Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2017 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":6108442,"source":{"system":"sec-edgar","filing":"0000899243-22-035380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035380/doc4.xml","form_type":"4"}},{"id":2124555,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-04T17:58:08.000Z","date":"2022-11-03","kind":"sale","acquired":false,"shares":1755,"price":33.8373,"value":59384.4615,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.62 to $34.27, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"(Continued Footnote 11) except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4308630,"source":{"system":"sec-edgar","filing":"0000899243-22-035228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035228/doc4.xml","form_type":"4"}},{"id":2124554,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-04T17:58:08.000Z","date":"2022-11-03","kind":"sale","acquired":false,"shares":25534,"price":33.1384,"value":846155.9056,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.62 to $33.61, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"(Continued Footnote 11) except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4310385,"source":{"system":"sec-edgar","filing":"0000899243-22-035228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035228/doc4.xml","form_type":"4"}},{"id":2124553,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-04T17:58:08.000Z","date":"2022-11-03","kind":"sale","acquired":false,"shares":22279,"price":32.3155,"value":719957.0245,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.62 to $32.61, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"(Continued Footnote 11) except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4335919,"source":{"system":"sec-edgar","filing":"0000899243-22-035228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035228/doc4.xml","form_type":"4"}},{"id":2124552,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-04T17:58:08.000Z","date":"2022-11-03","kind":"other","acquired":false,"shares":49569,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By GV 2017 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a pro rata in-kind distribution, for no consideration, by GV 2017, L.P. (the \"2017 Partnership\") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2017 Partnership's affiliate, Alphabet Holdings LLC (\"Alphabet Holdings\"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are directly held by the 2017 Partnership. The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the \"2017 GP\"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. (\"GV 2017 LLC\"). The sole managing member of GV 2017 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI Holdings Inc. (\"XXVI\"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of the 2017 GP but does not have voting or dispositive power over the shares held by the 2017 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2017 Partnership"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued Footnote 2) except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":6157025,"source":{"system":"sec-edgar","filing":"0000899243-22-035228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035228/doc4.xml","form_type":"4"}},{"id":2124551,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-04T17:58:08.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":8930,"price":36.775,"value":328400.75,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.60 to $37.03, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"(Continued Footnote 11) except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4358198,"source":{"system":"sec-edgar","filing":"0000899243-22-035228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035228/doc4.xml","form_type":"4"}},{"id":2124550,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-04T17:58:08.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":10372,"price":36.2786,"value":376281.6392,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.60 to $36.595, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"(Continued Footnote 11) except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4367128,"source":{"system":"sec-edgar","filing":"0000899243-22-035228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035228/doc4.xml","form_type":"4"}},{"id":2124549,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-04T17:58:08.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":9350,"price":34.7754,"value":325149.99,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.56 to $38.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnotes 4 through 9 of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"(Continued Footnote 11) except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4377500,"source":{"system":"sec-edgar","filing":"0000899243-22-035228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035228/doc4.xml","form_type":"4"}},{"id":2124548,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-04T17:58:08.000Z","date":"2022-11-02","kind":"other","acquired":false,"shares":28651,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By GV 2017 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a pro rata in-kind distribution, for no consideration, by GV 2017, L.P. (the \"2017 Partnership\") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2017 Partnership's affiliate, Alphabet Holdings LLC (\"Alphabet Holdings\"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are directly held by the 2017 Partnership. The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the \"2017 GP\"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. (\"GV 2017 LLC\"). The sole managing member of GV 2017 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI Holdings Inc. (\"XXVI\"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of the 2017 GP but does not have voting or dispositive power over the shares held by the 2017 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2017 Partnership"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued Footnote 2) except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":6206594,"source":{"system":"sec-edgar","filing":"0000899243-22-035228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322035228/doc4.xml","form_type":"4"}},{"id":2127264,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T21:02:26.000Z","date":"2022-11-01","kind":"sale","acquired":false,"shares":260,"price":38.6385,"value":10046.01,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.59 to $38.65, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"(Continued from footnote 12) Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4386850,"source":{"system":"sec-edgar","filing":"0000899243-22-034842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322034842/doc4.xml","form_type":"4"}},{"id":2127263,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T21:02:26.000Z","date":"2022-11-01","kind":"sale","acquired":false,"shares":2377,"price":37.821,"value":89900.517,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.35 to $38.30, inclusive"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"(Continued from footnote 12) Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4387110,"source":{"system":"sec-edgar","filing":"0000899243-22-034842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322034842/doc4.xml","form_type":"4"}},{"id":2127262,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T21:02:26.000Z","date":"2022-11-01","kind":"sale","acquired":false,"shares":29326,"price":36.6878,"value":1075906.4228,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.34 to $37.33, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"(Continued from footnote 12) Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4389487,"source":{"system":"sec-edgar","filing":"0000899243-22-034842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322034842/doc4.xml","form_type":"4"}},{"id":2127261,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T21:02:26.000Z","date":"2022-11-01","kind":"other","acquired":false,"shares":31963,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By GV 2017 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a pro rata in-kind distribution, for no consideration, by GV 2017, L.P. (the \"2017 Partnership\") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2017 Partnership's affiliate, Alphabet Holdings LLC (\"Alphabet Holdings\"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are directly held by the 2017 Partnership. The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the \"2017 GP\"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. (\"GV 2017 LLC\"). The sole managing member of GV 2017 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI Holdings Inc. (\"XXVI\"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from footnote 2) Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of the 2017 GP but does not have voting or dispositive power over the shares held by the 2017 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2017 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":6235245,"source":{"system":"sec-edgar","filing":"0000899243-22-034842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322034842/doc4.xml","form_type":"4"}},{"id":2127260,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T21:02:26.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":88,"price":40.6445,"value":3576.716,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.61 to $40.69, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"(Continued from footnote 12) Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4418813,"source":{"system":"sec-edgar","filing":"0000899243-22-034842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322034842/doc4.xml","form_type":"4"}},{"id":2127259,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T21:02:26.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":6601,"price":40.1569,"value":265075.6969,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.6198 to $40.42, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"(Continued from footnote 12) Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4418901,"source":{"system":"sec-edgar","filing":"0000899243-22-034842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322034842/doc4.xml","form_type":"4"}},{"id":2127258,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T21:02:26.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":23275,"price":38.9432,"value":906402.98,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $39.5858, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"(Continued from footnote 12) Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4425502,"source":{"system":"sec-edgar","filing":"0000899243-22-034842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322034842/doc4.xml","form_type":"4"}},{"id":2127257,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T21:02:26.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":23732,"price":37.9061,"value":899587.5652,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by GV 2019, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $38.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 5 through 11 of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The securities reported in this row are directly held by GV 2019, L.P. (the \"2019 Partnership\"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the \"2019 GP\"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. (\"GV 2019 LLC\"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"(Continued from footnote 12) Dr. Yeshwant is an affiliate of 2019 GP but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4448777,"source":{"system":"sec-edgar","filing":"0000899243-22-034842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322034842/doc4.xml","form_type":"4"}},{"id":2127256,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T21:02:26.000Z","date":"2022-10-31","kind":"other","acquired":false,"shares":53697,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By GV 2017 L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a pro rata in-kind distribution, for no consideration, by GV 2017, L.P. (the \"2017 Partnership\") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2017 Partnership's affiliate, Alphabet Holdings LLC (\"Alphabet Holdings\"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are directly held by the 2017 Partnership. The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the \"2017 GP\"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. (\"GV 2017 LLC\"). The sole managing member of GV 2017 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI Holdings Inc. (\"XXVI\"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from footnote 2) Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Dr. Yeshwant is an affiliate of the 2017 GP but does not have voting or dispositive power over the shares held by the 2017 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2017 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":6267208,"source":{"system":"sec-edgar","filing":"0000899243-22-034842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924322034842/doc4.xml","form_type":"4"}},{"id":2144965,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-04T20:10:33.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":101010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full September 30, 2023, the one-year anniversary of the grant date, subject to the Reporting Person's continuous service on such vesting date, and subject to full acceleration upon the consummation of a Sale Event (as defined in the Issuer's 2021 Stock Option and Incentive Plan)."}],"balance_after":101010,"derivative":{"exercise_price":4.95,"expiration_date":"2032-09-30","underlying":"Common Stock","underlying_shares":101010},"source":{"system":"sec-edgar","filing":"0001104659-22-106024","document":"tm2227449-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000110465922106024/tm2227449-7_4seq1.xml","form_type":"4"}},{"id":2234311,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T17:01:06.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":15500,"derivative":{"exercise_price":14.04,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-22-036371","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000120919122036371/doc4.xml","form_type":"4"}},{"id":2659191,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-06-22T17:17:08.000Z","date":"2021-06-21","kind":"exercise","acquired":false,"shares":4104416,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Dr. Yeshwant is an affiliate of GV 2019 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2019, L.P. Dr. Yeshwant disclaims beneficial ownership of the shares held by GV 2019, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":443265},"source":{"system":"sec-edgar","filing":"0000899243-21-025307","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924321025307/doc4.xml","form_type":"4"}},{"id":2659190,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2021-06-22T17:17:08.000Z","date":"2021-06-21","kind":"exercise","acquired":false,"shares":37308792,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Dr. Yeshwant is an affiliate of GV 2019 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2019, L.P. Dr. Yeshwant disclaims beneficial ownership of the shares held by GV 2019, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4029244},"source":{"system":"sec-edgar","filing":"0000899243-21-025307","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924321025307/doc4.xml","form_type":"4"}},{"id":2659189,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-06-22T17:17:08.000Z","date":"2021-06-21","kind":"exercise","acquired":false,"shares":58528428,"ownership":{"direct":false,"nature":"By GV 2017, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by GV 2017, L.P. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Dr. Yeshwant is an affiliate of GV 2017 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2017, L.P. Dr. Yeshwant disclaims beneficial ownership of the shares held by GV 2017, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6320905},"source":{"system":"sec-edgar","filing":"0000899243-21-025307","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924321025307/doc4.xml","form_type":"4"}},{"id":2659188,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T17:17:08.000Z","date":"2021-06-21","kind":"exercise","acquired":true,"shares":443265,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Dr. Yeshwant is an affiliate of GV 2019 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2019, L.P. Dr. Yeshwant disclaims beneficial ownership of the shares held by GV 2019, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4472509,"source":{"system":"sec-edgar","filing":"0000899243-21-025307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924321025307/doc4.xml","form_type":"4"}},{"id":2659187,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T17:17:08.000Z","date":"2021-06-21","kind":"exercise","acquired":true,"shares":4029244,"ownership":{"direct":false,"nature":"By GV 2019 L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Dr. Yeshwant is an affiliate of GV 2019 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2019, L.P. Dr. Yeshwant disclaims beneficial ownership of the shares held by GV 2019, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":4029244,"source":{"system":"sec-edgar","filing":"0000899243-21-025307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924321025307/doc4.xml","form_type":"4"}},{"id":2659186,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T17:17:08.000Z","date":"2021-06-21","kind":"exercise","acquired":true,"shares":6320905,"ownership":{"direct":false,"nature":"By GV 2017, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by GV 2017, L.P. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Dr. Yeshwant is an affiliate of GV 2017 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2017, L.P. Dr. Yeshwant disclaims beneficial ownership of the shares held by GV 2017, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose."}],"balance_after":6320905,"source":{"system":"sec-edgar","filing":"0000899243-21-025307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924321025307/doc4.xml","form_type":"4"}},{"id":3855001,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-02T16:10:22.000Z","date":"2018-07-31","kind":"other","acquired":false,"shares":5786,"price":137,"value":792682.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Foundation Medicine, Inc., a Delaware corporation (the \"Company\") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the \"Merger Agreement\"), with Roche Holdings, Inc., a Delaware corporation (\"Parent\" or \"Roche\"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the \"Tender Offer\") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company."},{"field":"shares","element":"transactionShares","label":"F2","text":"The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-044937","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118044937/doc4.xml","form_type":"4"}},{"id":4237814,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-10T16:07:36.000Z","date":"2017-08-08","kind":"sale","acquired":false,"shares":4800,"price":40.01,"value":192048.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":5786,"source":{"system":"sec-edgar","filing":"0001209191-17-048412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117048412/doc4.xml","form_type":"4"}},{"id":4240110,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-08T16:04:18.000Z","date":"2017-08-04","kind":"exercise","acquired":false,"shares":13385,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":24.21,"exercise_date":"2015-06-18","expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":13385},"source":{"system":"sec-edgar","filing":"0001209191-17-048081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117048081/doc4.xml","form_type":"4"}},{"id":4240109,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-08T16:04:18.000Z","date":"2017-08-04","kind":"tax_withholding","acquired":false,"shares":8585,"price":37.75,"value":324083.75,"ownership":{"direct":true},"balance_after":10586,"source":{"system":"sec-edgar","filing":"0001209191-17-048081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117048081/doc4.xml","form_type":"4"}},{"id":4240108,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-08T16:04:18.000Z","date":"2017-08-04","kind":"exercise","acquired":true,"shares":13385,"price":24.21,"value":324050.85,"ownership":{"direct":true},"balance_after":19171,"source":{"system":"sec-edgar","filing":"0001209191-17-048081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117048081/doc4.xml","form_type":"4"}},{"id":4240107,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-08T16:04:18.000Z","date":"2017-08-04","kind":"sale","acquired":false,"shares":18072,"price":36.85,"value":665953.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.70 to $36.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":5786,"source":{"system":"sec-edgar","filing":"0001209191-17-048081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117048081/doc4.xml","form_type":"4"}},{"id":4274571,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":39274,"kind":"person","name":"Yeshwant Krishna","position":1,"cik":"0001585001","reported_name":"Yeshwant Krishna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-22T16:06:41.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":5786,"price":40.05,"value":231729.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted by the Issuer pursuant to its 2013 Stock Option and Incentive Plan and the Issuer's Non-Employee Director Compensation Policy. The restricted stock units vest on the earlier of June 20, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board of Directors, or immediately upon the death or disability of the director or upon a change-of-control of the Issuer."}],"balance_after":23858,"source":{"system":"sec-edgar","filing":"0001209191-17-041333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117041333/doc4.xml","form_type":"4"}}]}